Rigel Pharmaceuticals | RIGL - Current Assets


Rigel Pharmaceuticals reported $214.93M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Agenus USD 95.28M 38.15M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
Anika Therapeutics USD 93.56M 9.8M Mar/2026
Arrowhead Research USD 1.84B 665.36M Mar/2026
AstraZeneca USD 29.61B 890M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Celldex Therapeutics USD 459.22M 75.44M Mar/2026
Daiichi Sankyo JPY 2.1T 218.5B Dec/2025
Eli Lilly USD 54.84B 794M Mar/2026
Halozyme Therapeutics USD 1B 177.83M Mar/2026
Heron Therapeutics USD 228.98M 9.08M Mar/2026
Intrexon USD 23.72M 45.04M Jun/2024
Ionis Pharmaceuticals USD 2.94B 52M Mar/2026
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025
Ligand Pharmaceuticals USD 865.42M 33.14M Mar/2026
MacroGenics USD 182.52M 37.42M Mar/2026
Neurocrine Biosciences USD 2.44B 86.6M Mar/2026
Pfizer USD 42.82B 76M Mar/2026
Regeneron Pharmaceuticals USD 18.21B 187.3M Mar/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Veracyte USD 522.17M 33.8M Mar/2026